Meeting
2015 ASCO Annual Meeting
Updated results from CHAMPION-1, a phase I/II study investigating weekly carfilzomib with dexamethasone for patients (Pts) with relapsed or refractory multiple myeloma (RRMM).
Authors
James R. Berenson
Institute for Myeloma & Bone Cancer Research, Los Angeles, CA
James R. Berenson , Alan Cartmell , Alberto Bessudo , Roger M. Lyons , Wael A. Harb , Dimitrios Tzachanis , Morton Coleman , Ralph V. Boccia , Robert M. Rifkin , Priti Patel , Sandra Dixon , Jesus G. Berdeja
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Lymphoma and Plasma Cell Disorders
Track
Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia
Sub Track
Multiple Myeloma
Clinical Trial Registration Number
NCT01677858
Citation
J Clin Oncol 33, 2015 (suppl; abstr 8527)
DOI
10.1200/jco.2015.33.15_suppl.8527
Abstract #
8527
Poster Bd #
344
Abstract Disclosures
Similar Posters
Poster
2018 ASCO Annual Meeting
Phase I-b study of isatuximab + carfilzomib in relapsed and refractory multiple myeloma (RRMM).
First Author: Ajai Chari
Poster
2014 ASCO Annual Meeting
A phase I study of carfilzomib, lenalidomide, vorinostat, and dexamethasone (QUAD) in relapsed and/or refractory multiple myeloma (MM).
First Author: David H. Vesole
Poster
2013 ASCO Annual Meeting
MM-005: A phase I trial of pomalidomide, bortezomib, and low-dose dexamethasone (PVD) in relapsed and/or refractory multiple myeloma (RRMM).
First Author: Paul Gerard Guy Richardson
Poster
2013 ASCO Annual Meeting
Results of a phase I/II study (NCT01365559) of carfilzomib (CFZ) replacing bortezomib (BTZ) in BTZ-containing regimens for BTZ-treated patients (pts) with relapsed and refractory multiple myeloma (MM).
First Author: James R. Berenson